Table 1.

Features of 65 Patients with Graves' Ophthalmopathy at First and Last Observations

Feature	First observation	Last observation
Age	42.4±12.6 years (range: 13–83)	46.3±15.3 years (range: 16–83)
Sex	Males: 19; Females: 46	n/a
Smoking Habits	Non-smokers: 26	Non-smokers: 26
	Ex-smokers: 9	Ex-smokers: 16
	Current smokers: 30	Current smokers: 23
	Pack Years: 0.45 (IQR: 0–8.4; range: 0–70)	Pack Years: 0.6 (IQR: 0–9.5; range: 0–80)
GO duration (time since GO appearance)	7 months (IQR: 2–14; range: 1–24)	40 months (IQR: 18.7–75.5; range: 3–258)
TD duration (time since diagnosis)	11 months (IQR: 6–26.5; range: 1–24)	50 months (IQR: 21.7–95.5; range: 3–279)
Follow-up	31 months (IQR: 10.7–67.7; range: 1–203)	n/a
Thyroid diagnosis	Graves' disease: 56
	Autoimmune thyroiditis: 6	n/a
	Euthyroid GO: 3
Thyroid treatment	None: 16	None: 9
	MMI: 44	MMI: 12
	LT4: 5	RI and then LT4: 11
		TX and then LT4: 28
		Only LT4: 5
Thyroid status	Hyperthyroid: 13	Hyperthyroid: 0
	Untreated: 12	Euthyroid: 63
	On MMI: 1	Untreated: 4
	Euthyroid: 50	On MMI: 11
	Untreated: 4	After MMI: 5
	On MMI: 41	On LT4: 43
	On LT4 5	Hypothyroid: 2
	Hypothyroid: 2	On MMI: 1
	On MMI: 2	On LT4: 1
Thyroid volume	25 mL (IQR: 12–33; range: 1–224)	n/a
TRAb	6.6 U/L (IQR: 1.8–19.5; range: 0–285)	2.2 U/L (IQR: 0–7.6; range: 0–79)

Numerical values are reported as median, with the exception of age (mean±SD).

GO, Graves' ophthalmopathy; n/a, not applicable; IQR, interquartile range; TD, thyroid disease; MMI, methimazole; RI, radioiodine; TX, thyroidectomy; TRAb, anti-TSH receptor autoantibodies.